Zhi-Feng Zhu

Zhi-Feng Zhu

Auto-generated profile, based on publicly available information

Zhi-Feng Zhu

National Key Laboratory for Germplasm Innovation and Utilization of Horticultural Crops, Huazhong Agricultural University, Wuhan, Hubei 430070, PR China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Postharvest Biology and Technology
Verified
Journal Article
Closed access
HYHongbin Yang
Hongbin Yang
YZYunqian Zou
Yunqian Zou
XLXin Li
Xin Li
MZMingfei Zhang
Mingfei Zhang
ZZZhifeng Zhu
Zhifeng Zhu
YCYunjiang Cheng
Yunjiang Cheng

9 February 2008 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
XLXiaolei Li
Xiaolei Li
JLJun-Yan Liu
Jun-Yan Liu
RLRong Lu
Rong Lu
QXQiong Xu
Qiong Xu
ZZZhi-Feng Zhu
Zhi-Feng Zhu
ZYZhi Yao
Zhi Yao

21 November 2023 in LWT
Verified
Journal Article
Open access
MWMengxia Wu
Mengxia Wu
PWPing Wang
Ping Wang
FZFeng Zhu
Feng Zhu
ZZZhifeng Zhu
Zhifeng Zhu
XQXiaolu Qu
Xiaolu Qu
LZLinlin Zhong
Linlin Zhong

1 March 2016 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
ZYZhi Yao
Zhi Yao
YHYu-Ting Huang
Yu-Ting Huang
LZLan Zhao
Lan Zhao
ZFZheng Fu
Zheng Fu
MZMeng Zhao
Meng Zhao
RLRong Lu
Rong Lu
Therapeutic effects of tyroservatide on metastasis of lung cancer and its mechanism affecting integrin–focal adhesion kinase signal transduction Yu-ting Huang,1,* Lan Zhao,1,* Zheng Fu,1 Meng Zhao,1 Xiao-meng Song,1 Jing Jia,1 Song Wang,1 Jin-ping Li,1 Zhi-feng Zhu,1 Gang Lin,1,2 Rong Lu,1,2 Zhi Yao1,3 1Department of Immunology, Tianjin Medical University, Tianjin, 2Shenzhen Kangzhe Pharmaceutical Co., Ltd., Shenzhen, 3Key Laboratory of Immuno Microenvironment and Disease of the Educational Ministry of China, Tianjin Medical University, Tianjin, People’s Republic of China *These authors contributed equally to this paper Tyroservatide (YSV) can inhibit the growth and metastasis of mouse lung cancer significantly. This study investigated the therapeutic effects of tripeptide YSV on metastasis of human lung cancer cells and explored its possible mechanism that affects integrin–focal adhesion kinase (FAK) signal transduction in tumor cells. YSV significantly inhibited the adhesion and the invasion of highly metastatic human lung cancer cell lines 95D, A549, and NCI-H1299. In addition, YSV significantly inhibited phosphorylation of FAK Tyr397 and FAK Tyr576/577 in the 95D, A549, and NCI-H1299 human lung cancer cells in vitro. And the mRNA level and protein expression of FAK in these human lung cancer cells decreased at the same time. YSV also significantly inhibited mRNA and protein levels of integrin ß1 and integrin ß3 in the 95D, A549, and NCI-H1299 human lung cancer cells. Our research showed that YSV inhibited adhesion and invasion of human lung cancer cells and exhibited therapeutic effects on metastasis of lung cancer. Keywords: tyroservatide, integrin, focal adhesion kinase, FAK, MMP-2, MMP-9